Table Info

Table 2.

Inflammatory routine laboratory derived scores and association with outcomes to immunotherapy in RCC

Candidate biomarker	References	Year	Country	N	Tumor	Timepoint	Type of systemic therapy	Cut-off/Trend indicator	Findings
NLR	Bilen et al. [39]	2022	US	886	RCC	Pretreatment	Avelumab plus axitinib or sunitinib	High	Worse OS and PFS
NLR	Simonaggio et al. [42]	2020	France	161	RCC and NSCLC	On-treatment changes	Nivolumab	Increase	Worse OS and PFS
NLR	Young et al. [43]	2024	UK	132	RCC	Pretreatment On-treatment changes	ICI combinations	≥ 3 at baseline	NS trend for worse OS
								≥ 3 at 12 weeks	Worse OS
								Normalization of pre-treatment elevation	Superior OS and ORR
NLR	Ishihara et al. [136]	2019	Japan	58	RCC	Pretreatment	Nivolumab	≥ 3	Worse OS after MVA, worse PFS only on UVA
NLR	Suzuki et al. [137]	2020	Japan	65	RCC	Pretreatment	Nivolumab	≥ 5	Worse OS
NLR	Shirotake et al. [138]	2019	Japan	54	RCC	Pretreatment	Nivolumab	≥ Median value (2.89)	NS
NLR	Zahoor et al. [54]	2018	US	90	RCC	Pretreatment	Nivolumab	≥ 4.2	Worse PFS
NLR	Tucker et al. [56]	2021	US	110	RCC	Pretreatment	Nivolumab plus ipilimumab	≥ 3.42	Worse OS
LIPI	Meyers et al. [47]	2019	Canada	643	NSCLC, melanoma and RCC (145, 25%)	Pretreatment	ICI	Good LIPI, 0 factor	No difference in OS, PFS or ORR between the good and intermediate LIPI groups
								Intermediate LIPI, 1 factor
								Poor LIPI, 2 factors	Worse OS and PFS
LIPI	Carril-Ajuria et al. [48]	2024	France	1,084	ccRCC	Pretreatment	Nivolumab plus ipilimumab vs. sunitinib	Intermediate/Poor LIPI (1–2 factors) vs. good LIPI (0 factor)	Worse OS in both treatment arms
NER	Zhuang et al. [139]	2023	US	184	RCC	Pretreatment	ICI	High NER > 49.2	Worse OS No significant difference for PFS
NER	Tucker et al. [56]	2021	US	110	RCC	Pretreatment	Nivolumab plus ipilimumab	≥ Median value 26.4	Worse PFS, OS and ORR
PLR	Iinuma et al. [59]	2021	Japan	43	RCC	Pretreatment	Nivolumab plus ipilimumab	High Median 215.6	Poor PFS
SII	Iinuma et al. [59]	2021	Japan	43	RCC	Pretreatment	Nivolumab plus ipilimumab	Median SII of 730	Improved survival in the SII low

ccRCC: clear cell renal cell carcinoma; ICI: immune checkpoint inhibitors; LIPI: lung immune prognostic index; MVA: multivariate; UVA: univariate; NER: neutrophil-to-eosinophil ratio; NLR: neutrophil-to-lymphocyte ratio; NS: non-significant; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PLR: platelet-to-lymphocyte ratio; RCC: renal cell carcinoma; SII: systemic immune inflammation; UC: urothelial carcinoma; UK: United Kingdom; US: United States. Meta-analysis not included

Declarations

Author contributions

LO: Conceptualization, Investigation, Writing—original draft. MN: Visualization. RF, JGD, JPF, DN, CA, AAS, NC, GdV, and LA: Writing—review & editing. LCA: Conceptualization, Investigation, Writing—original draft.

Conflicts of interest

RF: Honoraria: Bayer, Astellas, Janssen, BMS, MSD, Ipsen, Pfizer, Merck, Astra Zeneca. NC has provided expertise through participation in scientific advisory boards to AstraZeneca and to Servier and received a research grant from Cytune Pharma, Roche, and Sanofi, although these grants were not on the matter of this manuscript. GdV: grants and personal fees from Pfizer, Roche, and Ipsen; and personal fees from Bristol-Myers Squibb, Astellas, Janssen, Bayer, Merck, and MSD. LA: Consulting or Advisory Role: Astellas Pharma (Inst), Bristol:Myers Squibb (Inst), Eisai (Inst), Ipsen (Inst), Janssen (Inst), MSD (Inst), Pfizer (Inst), Roche (Inst). Travel, Accommodations, Expenses: BMS, Ipsen, MSD. LCA: Travel/accomodation: Pfizer, Ipsen, BMS. Honoraria: Ipsen, Janssen. The rest of authors declare no competing interests.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. [DOI] [PubMed]

Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, et al. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn. 2020;20:141–50. [DOI] [PubMed]

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. [DOI] [PubMed] [PMC]

Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376:354–66. [DOI] [PubMed]

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973–80. [DOI] [PubMed]

Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:71–90. [DOI] [PubMed] [PMC]

Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy. 2021;13:685–92. [DOI] [PubMed]

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1103–15. [DOI] [PubMed] [PMC]

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al.; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384:1289–300. [DOI] [PubMed]

10.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al.; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384:829–41. [DOI] [PubMed] [PMC]

11.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al.; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378:1277–90. [DOI] [PubMed] [PMC]

12.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al.; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1116–27. [DOI] [PubMed]

13.

Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment Landscape of Renal Cell Carcinoma. Curr Treat Options Oncol. 2023;24:1889–916. [DOI] [PubMed] [PMC]

14.

Pezzicoli G, Ganini C, Re Sartò GV, Pirovano M, Cosmai L, Porta C. The Treatment of Metastatic Renal Cell Carcinoma: An Update. G Ital Nefrol. 2023;40:2023–S81. Italian. [PubMed]

15.

Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30:1448–59. [DOI] [PubMed]

16.

Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26:1733–41. [DOI] [PubMed] [PMC]

17.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24:749–57. [DOI] [PubMed] [PMC]

18.

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10:e004316. [DOI] [PubMed] [PMC]

19.

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5. [DOI] [PubMed] [PMC]

20.

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. [DOI] [PubMed] [PMC]

21.

Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356–71. [DOI] [PubMed]

22.

Gardner A, Ruffell B. Dendritic Cells and Cancer Immunity. Trends Immunol. 2016;37:855–65. [DOI] [PubMed] [PMC]

23.

Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61. [DOI] [PubMed] [PMC]

24.

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. [DOI] [PubMed] [PMC]

25.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416. [DOI] [PubMed] [PMC]

26.

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74–80. [DOI] [PubMed]

27.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55. [DOI] [PubMed] [PMC]

28.

Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, et al. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. J Immunother Cancer. 2022;10:e004885. [DOI] [PubMed] [PMC]

29.

Viant C, Wirthmiller T, ElTanbouly MA, Chen ST, Kara EE, Cipolla M, et al. Germinal center-dependent and -independent memory B cells produced throughout the immune response. J Exp Med. 2021;218:e20202489. [DOI] [PubMed] [PMC]

30.

Dogan I, Bertocci B, Vilmont V, Delbos F, Mégret J, Storck S, et al. Multiple layers of B cell memory with different effector functions. Nat Immunol. 2009;10:1292–9. [DOI] [PubMed]

31.

Yuan S, Liu Y, Till B, Song Y, Wang Z. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy. Front Immunol. 2020;11:563653. [DOI] [PubMed] [PMC]

32.

Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, et al. Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. Front Immunol. 2022;13:840207. [DOI] [PubMed] [PMC]

33.

Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, et al. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunol Res. 2023;11:1114–24. [DOI] [PubMed] [PMC]

34.

Guo L, Bi X, Li Y, Wen L, Zhang W, Jiang W, et al. Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. J Pathol. 2020;251:26–37. [DOI] [PubMed] [PMC]

35.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40. [DOI] [PubMed]

36.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9. [DOI] [PubMed]

37.

Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5:e006404. [DOI] [PubMed] [PMC]

38.

Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol. 2020;20:90. [DOI] [PubMed] [PMC]

39.

Bilen MA, Rini BI, Voss MH, Larkin J, Haanen JBAG, Albiges L, et al. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin Cancer Res. 2022;28:738–47. [DOI] [PubMed] [PMC]

40.

Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642. [DOI] [PubMed] [PMC]

41.

Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open. 2022;7:100634. [DOI] [PubMed] [PMC]

42.

Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother. 2020;69:2513–22. [DOI] [PubMed] [PMC]

43.

Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, et al. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Clin Genitourin Cancer. 2024;22:102072. [DOI] [PubMed]

44.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4:351–7. [DOI] [PubMed] [PMC]

45.

Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. J Thorac Oncol. 2019;14:1440–6. [DOI] [PubMed]

46.

Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5:1481–5. [DOI] [PubMed] [PMC]

47.

Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, et al. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2019;11:1713. [DOI] [PubMed] [PMC]

48.

Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, et al. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. Eur J Cancer. 2024;204:114048. [DOI] [PubMed]

49.

Parent P, Auclin E, Patrikidou A, Mezquita L, Martínez Chanzá N, Dumont C, et al. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. Cancers (Basel). 2023;15:1066. [DOI] [PubMed] [PMC]

50.

Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, et al. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers (Basel). 2021;13:3776. [DOI] [PubMed] [PMC]

51.

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, et al. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol. 2024;54:722–9. [DOI] [PubMed]

52.

Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609–17. [DOI] [PubMed]

53.

Simon SCS, Hu X, Panten J, Grees M, Renders S, Thomas D, et al. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. Oncoimmunology. 2020;9:1727116. [DOI] [PubMed] [PMC]

54.

Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6:107. [DOI] [PubMed] [PMC]

55.

Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X, Mahammedi H. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Med. 2021;10:6705–13. [DOI] [PubMed] [PMC]

56.

Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9:80. [DOI] [PubMed] [PMC]

57.

Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, et al. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers (Basel). 2022;14:3830. [DOI] [PubMed] [PMC]

58.

Xu H, He A, Liu A, Tong W, Cao D. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Int Immunopharmacol. 2019;77:105957. [DOI] [PubMed]

59.

Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J Clin Med. 2021;10:5325. [DOI] [PubMed] [PMC]

60.

Wang Y, Ni Q. Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. Ann Med. 2023;55:808–19. [DOI] [PubMed] [PMC]

61.

Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167:397–404.e9. [DOI] [PubMed] [PMC]

62.

Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, et al. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. Clin Cancer Res. 2017;23:587–99. [DOI] [PubMed]

63.

Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, et al. Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2021;9:e001823. [DOI] [PubMed] [PMC]

64.

Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465–75. [DOI] [PubMed]

65.

Fousek K, Horn LA, Palena C. Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692. [DOI] [PubMed] [PMC]

66.

Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N, et al. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. Cell Signal. 2017;32:48–58. [DOI] [PubMed]

67.

Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26:688–92. [DOI] [PubMed] [PMC]

68.

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74. [DOI] [PubMed] [PMC]

69.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017;23:4416–28. [DOI] [PubMed]

70.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13:827–37. [DOI] [PubMed]

71.

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26:693–8. [DOI] [PubMed] [PMC]

72.

Carril-Ajuria L, Naigeon M, Dalban C, Desnoyer A, Rioux-Leclercq N, Sautès-Fridma C n, et al. Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. JCO. 2023;41:724. [DOI]

73.

Ajuria LC, Naigeon M, Flippot R, Dalban C, Desnoyer A, Rioux-Leclercq N, et al. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. Immunooncol Technol. 2023;20:100643. [DOI]

74.

Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clin Transl Oncol. 2020;22:835–43. [DOI] [PubMed]

75.

Sang YB, Yang H, Lee WS, Lee SJ, Kim SG, Cheon J, et al. High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers (Basel). 2022;14:5985. [DOI] [PubMed] [PMC]

76.

Epaillard N, Simonaggio A, Elaidi R, Azzouz F, Braychenko E, Thibault C, et al. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bull Cancer. 2020;107:eS22–7. [DOI] [PubMed]

77.

Martini JF, Plimack ER, Choueiri TK, McDermott DF, Puzanov I, Fishman MN, et al. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clin Cancer Res. 2020;26:5598-608. [DOI] [PubMed]

78.

Choueiri TK, Donahue AC, Rini BI, Powles T, Haanen JBAG, Larkin J, et al. Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). JCO. 2021;39:4547. [DOI]

79.

Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978–85. [DOI] [PubMed] [PMC]

80.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8. [DOI] [PubMed]

81.

Massouh Skorin R, Escovar la Riva P, Gabler F, Kirmayr M, Khamis T, Escobar S, et al. Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. Actas Urol Esp (Engl Ed). 2023;47:271–8. [DOI] [PubMed]

82.

Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer. 2022;10:e003527. [DOI] [PubMed] [PMC]

83.

Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, et al. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. Int J Mol Sci. 2022;23:14496. [DOI] [PubMed] [PMC]

84.

Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, et al. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. Oncoimmunology. 2020;9:1846901. [DOI] [PubMed] [PMC]

85.

Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology. 2020;9:1832348. [DOI] [PubMed] [PMC]

86.

Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009;229:216–31. [DOI] [PubMed]

87.

Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol. 2013;190:6250–8. [DOI] [PubMed] [PMC]

88.

Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003;4:49–54. [DOI] [PubMed]

89.

Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, et al. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma. Clin Cancer Res. 2022;28:4983–94. [DOI] [PubMed]

90.

Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, et al. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clin Cancer Res. 2021;27:3397–403. [DOI] [PubMed] [PMC]

91.

Albiges L, Bex A, Suárez C, Uzzo R, Tang X, Assaf ZJ, et al. Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. JCO. 2024;42:4506. [DOI]

92.

Lucarelli G, Rutigliano M, Loizzo D, di Meo NA, Lasorsa F, Mastropasqua M, et al. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome. Int J Mol Sci. 2022;23:13968. [DOI] [PubMed] [PMC]

93.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9:132. [DOI] [PubMed] [PMC]

94.

Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI. Blood-based tumor biomarkers in lung cancer for detection and treatment. Transl Lung Cancer Res. 2017;6:648–60. [DOI] [PubMed] [PMC]

95.

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18:5701–10. [DOI] [PubMed]

96.

Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:2473–80. [DOI] [PubMed]

97.

Ma X, Xiao Z, Li X, Wang F, Zhang J, Zhou R, et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol. 2014;35:5551–60. [DOI] [PubMed]

98.

Wang S, Zheng G, Cheng B, Chen F, Wang Z, Chen Y, et al. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature. PLoS One. 2014;9:e99259. [DOI] [PubMed] [PMC]

99.

Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med. 2015;3:36. [DOI] [PubMed] [PMC]

100.

Cao L, Yang W, Zhao X, Chen Z. Diagnostic and prognostic value of circulating tumor cells in renal cell cancer: A systematic review and meta-analysis. Asian J Surg. 2024;47:3425–34. [DOI] [PubMed]

101.

Smit DJ, Pantel K. Circulating tumor cells as liquid biopsy markers in cancer patients. Mol Aspects Med. 2024;96:101258. [DOI] [PubMed]

102.

Song J, Yu Z, Dong B, Zhu M, Guo X, Ma Y, et al. Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. World J Surg Oncol. 2021;19:156. [DOI] [PubMed] [PMC]

103.

Guan Y, Xu F, Tian J, Wang Y, Guo N, Wan Z, et al. Prognostic value of circulating tumor cells and immune-inflammatory cells in patients with renal cell carcinoma. Urol Oncol. 2022;40:167.e21–32. [DOI] [PubMed]

104.

Wang Q, Li Z, Zhai W, Zheng J. Clinical values of circulating tumor cells count in localized renal cell carcinoma. Transl Cancer Res. 2023;12:2351–60. [DOI] [PubMed] [PMC]

105.

Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, et al. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist. 2021;26:740–50. [DOI] [PubMed] [PMC]

106.

Bootsma M, McKay RR, Emamekhoo H, Bade RM, Schehr JL, Mannino MC, et al. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. J Clin Oncol. 2022;40:3633–41. [DOI] [PubMed] [PMC]

107.

Kim H, Park KU. Clinical Circulating Tumor DNA Testing for Precision Oncology. Cancer Res Treat. 2023;55:351–66. [DOI] [PubMed] [PMC]

108.

Feng G, Ye X, Fang F, Pu C, Huang H, Li G. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers. 2013;34:105–11. [DOI] [PubMed] [PMC]

109.

Skrypkina I, Tsyba L, Onyshchenko K, Morderer D, Kashparova O, Nikolaienko O, et al. Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer. Dis Markers. 2016;2016:3693096. [DOI] [PubMed] [PMC]

110.

de Martino M, Klatte T, Haitel A, Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2012;118:82–90. [DOI] [PubMed]

111.

Lasseter K, Nassar AH, Hamieh L, Berchuck JE, Nuzzo PV, Korthauer K, et al. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genet Med. 2020;22:1366–73. [DOI] [PubMed]

112.

Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. Eur Urol Open Sci. 2022;37:27–35. [DOI] [PubMed] [PMC]

113.

Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018;24:3528–38. [DOI] [PubMed]

114.

Park JS, Kim H, Jang WS, Kim J, Ham WS, Lee ST. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy. Cancer Sci. 2024;115:1680–7. [DOI] [PubMed] [PMC]

115.

Smigelski M, Sudhaman S, Nagpal S, Brooks B, Gerald T, Sanchez-Mendez R, et al. 1908P Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC). Ann Oncol. 2023;34:S1027. [DOI]

116.

Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, et al. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clin Chim Acta. 2016;452:109–19. [DOI] [PubMed]

117.

Yamamoto Y, Uemura M, Fujita M, Maejima K, Koh Y, Matsushita M, et al. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci. 2019;110:617–28. [DOI] [PubMed] [PMC]

118.

Kotecha RR, Gedvilaite E, Ptashkin R, Knezevic A, Murray S, Johnson I, et al. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precis Oncol. 2022;6:e2200012. [DOI] [PubMed] [PMC]

119.

Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, et al. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer. 2017;1:65–70. [DOI] [PubMed] [PMC]

120.

Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, et al. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2023;7:e2200543. [DOI] [PubMed] [PMC]

121.

Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865–77. [DOI] [PubMed] [PMC]

122.

Huang G, Li H, Wang J, Peng X, Liu K, Zhao L, et al. Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma. Pathol Res Pract. 2020;216:153152. [DOI] [PubMed]

123.

Huang G, Li X, Chen Z, Wang J, Zhang C, Chen X, et al. A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma. Pathol Oncol Res. 2020;26:2425–34. [DOI] [PubMed]

124.

Chen X, Li R, Li X, Peng X, Zhang C, Liu K, et al. Identification of a four-microRNA panel in serum for screening renal cell carcinoma. Pathol Res Pract. 2021;227:153625. [DOI] [PubMed]

125.

Cinque A, Vago R, Trevisani F. Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose. Genes (Basel). 2021;12:835. [DOI] [PubMed] [PMC]

126.

Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G, et al. Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma. Sci Rep. 2024;14:8603. [DOI] [PubMed] [PMC]

127.

Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Invest. 2018;128:5505–16. [DOI] [PubMed] [PMC]

128.

Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, et al. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. Cancer Immunol Res. 2019;7:1013–24. [DOI] [PubMed]

129.

Li R, Chen W, Lu C, Li X, Chen X, Huang G, et al. A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis. Front Oncol. 2023;12:1076303. [DOI] [PubMed] [PMC]

130.

Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 2008;28:621–9. [DOI] [PubMed] [PMC]

131.

Labadie BW, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. Clin Cancer Res. 2019;25:1462–71. [DOI] [PubMed] [PMC]

132.

Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74. [DOI] [PubMed]

133.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389–402. [DOI] [PubMed] [PMC]

134.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083–97. [DOI] [PubMed]

135.

Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019;10:4346. [DOI] [PubMed] [PMC]

136.

Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, et al. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Target Oncol. 2019;14:453–63. [DOI] [PubMed]

137.

Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2020;25:135–44. [DOI] [PubMed]

138.

Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, et al. Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma. Anticancer Res. 2019;39:4371–7. [DOI] [PubMed]

139.

Zhuang TZ, Ravindranathan D, Liu Y, Martini DJ, Brown JT, Nazha B, et al. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2023;28:239–45. [DOI] [PubMed] [PMC]

140.

Mauge L, Galy-Fauroux I, Elaidi RT, Ben Dhia L, Bertil S, Bennamoun M, et al. 686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial. Ann Oncol. 2021;32:S704. [DOI]